article

1. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy..  The oncologist.  29:870-877. 2024
2. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review..  Future oncology (London, England).  20:1-16. 2024
3. Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)..  European urology oncology.  2024
4. Current developments in prehabilitation in urologic oncology..  Current opinion in urology.  34:477-483. 2024
5. Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management..  European urology focus.  2024
6. Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey..  JCO oncology practice.  -. 2024
7. Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide..  Practical radiation oncology.  2024
8. A Multicenter Evaluation of Treatment-associated Changes in Body Composition in Men With Germ Cell Tumors of the Testis: Implications for Adverse Events and Complications..  Urology.  74-82. 2024
9. Stable Lateral Compression Pelvic Ring Injury Requiring Operative Treatment due to Bladder Impingement: A Case Report..  JBJS case connector.  14. 2024
10. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer..  Clinical genitourinary cancer.  22:-. 2024
11. Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer..  European urology oncology.  2024
12. Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy..  Clinical genitourinary cancer.  22:-. 2024
13. Prehabilitation: A multidimensional adjunct to comprehensive personalized oncologic care. But, can we make it pragmatic?.  European urology focus.  10:1-3. 2024
14. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review..  JAMA oncology.  10:240-248. 2024
15. Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials..  Urologic oncology.  42:223-228. 2024
16. Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker..  The oncologist.  28:e1219-e1229. 2023
17. Bladder cancer oligometastases - definition and treatment..  Nature reviews. Urology.  20:701-702. 2023
18. Surgically Feasible? Yes. But Is It the Right Option? It Depends..  International journal of radiation oncology, biology, physics.  117:-. 2023
19. Emerging Role of Mobile Applications and Wearable Devices for Prehabilitation in Urologic Oncology..  European urology focus.  10:20-22. 2023
20. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  41:5437-5447. 2023
21. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer..  Bladder cancer (Amsterdam, Netherlands).  9:271-286. 2023
22. Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma..  Frontiers in oncology.  -. 2023
23. Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis..  Clinical genitourinary cancer.  21:694-702. 2023
24. The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma..  Cancers.  15. 2023
25. Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy..  European urology oncology.  7:112-121. 2023
26. Engaging disparities in prostate cancer: Piloting an interactive, virtual workshop to educate providers on shared decision-making for underserved populations..  Urologic oncology.  41:430.e1-430.e7. 2023
27. Adding Stereotactic Radiation to the Multidisciplinary Armamentarium for Localized Renal Cell Carcinoma: Ready for Primetime? : An Editorial Regarding a Recent 5-Year Efficacy and Safety Report of a Multicenter Cohort of Primary RCC Patients Treated with SABR..  Annals of surgical oncology.  30:6947-6949. 2023
28. Surgical Management of Localized Disease and Small Renal Masses..  Hematology/oncology clinics of North America.  37:877-892. 2023
29. Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19..  The oncologist.  28:494-500. 2023
30. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline..  The Journal of urology.  209:1071-1081. 2023
31. Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus..  Clinical genitourinary cancer.  21:475-482.e4. 2023
32. Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma..  Current urology reports.  24:317-334. 2023
33. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy..  Clinical genitourinary cancer.  21:507.e1-507.e14. 2023
34. Robot-assisted retroperitoneal lymph node dissection: a systematic review of perioperative outcomes..  BJU international.  132:9-30. 2023
35. Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review..  European urology focus.  9:631-636. 2023
36. Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: Study protocol for a randomized, controlled pilot and feasibility study..  Contemporary clinical trials communications.  -. 2022
37. Clinic friendly estimation of muscle composition: Preoperative linear segmentation shows overall survival correlated with muscle mass in patients with nonmetastatic renal cell carcinoma..  Frontiers in oncology.  -. 2022
38. Data regarding covariates significantly associated with sarcopenia and varying albumin statuses in patients with renal cell carcinoma..  Data in brief.  -. 2022
39. Epidemiology, Screening, and Prevention of Bladder Cancer..  European urology oncology.  5:628-639. 2022
40. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy..  Urologic oncology.  41:51.e25-51.e31. 2022
41. Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma..  Urologic oncology.  41:50.e19-50.e26. 2022
42. Epidemiology of Renal Cell Carcinoma: 2022 Update..  European urology.  82:529-542. 2022
43. Role of cytoreductive surgery in the era of immunotherapy..  Current opinion in urology.  32:618-626. 2022
44. A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes..  The Journal of urology.  208:542-560. 2022
45. Reply by Authors..  The Journal of urology.  208:-. 2022
46. Reply by Authors..  The Journal of urology.  208:-. 2022
47. Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events..  Urologic oncology.  40:456.e19-456.e30. 2022
48. Naloxegol versus Alvimopan for Enhancing Postoperative Recovery following Radical Cystectomy for Bladder Cancer..  Urology practice.  9:364-370. 2022
49. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group..  European urology oncology.  5:505-516. 2022
50. Gender Disparities Among Editorial Boards of International Urology Journals..  European urology focus.  8:1840-1846. 2022
51. Shapeshifters in Pathology: Paratesticular Solitary Fibrous Tumor Mimicking Leiomyoma..  International journal of surgical pathology.  30:-. 2022
52. Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis..  Minerva urology and nephrology.  74:518-527. 2022
53. EDITORIAL COMMENT..  Urology.  103-104. 2022
54. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma..  Cancer medicine.  11:3106-3114. 2022
55. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma..  Cancer.  128:2073-2084. 2022
56. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis..  European urology.  81:414-425. 2022
57. Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis..  Urologic oncology.  40:197.e11-197.e23. 2022
58. Muscle Mass Matters in Patients with Renal Cell Carcinoma, but That Is Only the Beginning…..  Annals of surgical oncology.  29:2152-2154. 2022
59. Redefining the Gender Gap in Urology Authorship: An 18-Year Publication Analysis..  European urology focus.  8:1512-1519. 2021
60. Metastasectomy in kidney cancer: current indications and treatment approaches..  Current opinion in supportive and palliative care.  15:266-275. 2021
61. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis..  European urology.  81:576-585. 2021
62. A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy..  Advances in radiation oncology.  7:-. 2021
63. Reply to Kenta Ushida, Miho Shimizu, and Ryo Momosaki's Letter to the Editor re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.05.015. Strategies for Effective Prehabilitation in Urologic Cancer..  European urology.  80:e141-e142. 2021
64. The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium..  European urology.  80:450-453. 2021
65. Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic..  Urologic oncology.  41:65-68. 2021
66. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review..  European urology.  81:157-167. 2021
67. A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers..  Urologic oncology.  39:595-601. 2021
68. Research highlights of the 2020 society of urologic oncology young urologic oncologists' program..  Urologic oncology.  39:452-454. 2021
69. Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action..  European urology oncology.  4:396-404. 2021
70. Machine Learning in Body Composition Analysis..  European urology focus.  7:713-716. 2021
71. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma..  Cancer.  127:1974-1983. 2021
72. Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos..  Journal of visualized experiments : JoVE.  2021
73. Advances in the Characterization of Clear Cell Papillary Renal Cell Carcinoma: Identifying the Sheep in Wolf's Clothing..  European urology.  79:478-479. 2021
74. Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy..  Urologic oncology.  39:496.e1-496.e8. 2021
75. The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: A systematic review and meta-analysis..  Arab journal of urology.  19:98-103. 2021
76. Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015..  Urology.  154-160. 2020
77. Female Authorship Trends in Urology During the COVID-19 Pandemic..  European urology.  79:322-324. 2020
78. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program..  Clinical genitourinary cancer.  19:144-154. 2020
79. Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements..  European journal of radiology.  -. 2020
80. Women in Leadership in Urology: The Case for Increasing Diversity and Equity..  Urology.  16-24. 2020
81. Prostate cancer presentation, treatment selection, and outcomes among men with HIV/AIDS: A clinical stage, race, and age-matched contemporary analysis..  Urologic oncology.  39:73.e19-73.e25. 2020
82. Assessing Contemporary Trends in Female Speakership within Urologic Oncology..  Urology.  41-46. 2020
83. Predictive Risk Factors for Continued Smoking after the Diagnosis of a Genitourinary Malignancy..  Urology.  178-185. 2020
84. Introduction: Personalizing risk stratification in bladder cancer: Moving away from "the eyeball test" and embracing objective quantification of risk..  Urologic oncology.  38:695-697. 2020
85. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma..  Cancer.  126:3912-3915. 2020
86. Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients..  American journal of therapeutics.  28:e380-e387. 2020
87. Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels..  Journal of the National Cancer Institute.  112:384-390. 2020
88. Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes..  Bladder cancer (Amsterdam, Netherlands).  6:71-81. 2020
89. Low diagnostic sensitivity of cystoscopy and cystography of surgically confirmed vesicoenteric fistulae..  International urology and nephrology.  52:1203-1208. 2020
90. Risk stratification metrics for bladder cancer: Comprehensive Geriatric Assessments..  Urologic oncology.  38:725-733. 2020
91. Xanthogranulomatous Pyelonephritis With Direct Extension Into the Liver..  The American journal of medicine.  133:1054-1055. 2020
92. Reply by Authors..  The Journal of urology.  203:-. 2019
93. Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication..  The Journal of urology.  202:936-943. 2019
94. Reply by Authors..  The Journal of urology.  202:-. 2019
95. Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  276-283. 2019
96. MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement..  Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.  44:814-819. 2019
97. Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer..  Scandinavian journal of urology.  52:340-348. 2019
98. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer..  Bladder cancer (Amsterdam, Netherlands).  4:411-418. 2018
99. Early Complications and Mortality following Radical Cystectomy: Associations with Malnutrition and Obesity..  Bladder cancer (Amsterdam, Netherlands).  4:377-388. 2018
100. Epithelioid angiomyolipoma metastasis to the rectus abdominis..  The Canadian journal of urology.  25:9527-9529. 2018
101. Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape..  European urology focus.  4:731-732. 2018
102. Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients..  European urology oncology.  1:292-304. 2018
103. Role of metastasis-directed treatment in kidney cancer..  Cancer.  124:3641-3655. 2018
104. T4 urothelial carcinoma in undiagnosed closed bladder exstrophy in a post-menopausal female..  The Canadian journal of urology.  25:9214-9216. 2018
105. Usefulness of Preoperative Ultrasound for the Evaluation of Testicular Rupture in the Setting of Scrotal Gunshot Wounds..  The Journal of urology.  199:1546-1551. 2018
106. Testis cancer incidentally found following delayed presentation of traumatic testicular rupture..  Urology case reports.  32-34. 2017
107. Validation study of a new semi-automated software program for CT body composition analysis..  Abdominal radiology (New York).  42:2369-2375. 2017
108. Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model..  Urology.  32-37. 2017
109. Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort..  Urologic oncology.  35:662.e17-662.e21. 2017
110. Oncologic surveillance following radical cystectomy: an individualized risk-based approach..  World journal of urology.  35:1863-1869. 2017
111. Metastatic Adenocarcinoma of the Prostate Presenting as Supraclavicular and Bulky Generalized Lymphadenopathy with a Benign Digital Rectal Exam..  Urology case reports.  128-130. 2017
112. National treatment trends among older patients with T1-localized renal cell carcinoma..  Urologic oncology.  35:113.e15-113.e21. 2016
113. A 53-Year-Old Man With Dysuria, Pyuria, and Genital Ulcers..  Arthritis care & research.  68:1371-7. 2016
114. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes..  BJU international.  119:116-127. 2016
115. Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study..  Urology.  155-161. 2016
116. Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma..  Urology.  106-113. 2016
117. Urethral Foreign Bodies: Clinical Presentation and Management..  Urology.  257-260. 2016
118. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?.  The Journal of urology.  195:1754-9. 2015
119. Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series..  Urology practice.  3:124-133. 2015
120. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  33:4151-7. 2015
121. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer..  The Journal of urology.  195:270-6. 2015
122. Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma..  Therapeutic advances in urology.  7:216-29. 2015
123. Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma..  BJU international.  117:E60-6. 2015
124. Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals..  European urology focus.  2:172-179. 2015
125. Reply to Pascal Mouracade's letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9..  European urology.  68:e84-5. 2015
126. Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach..  Urologic oncology.  33:339.e1-8. 2015
127. Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus..  BJU international.  116:388-96. 2015
128. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy..  Urologic oncology.  33:388.e11-8. 2015
129. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization..  Urology.  85:442-50. 2015
130. Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting..  The Journal of urology.  193:1507-13. 2014
131. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  32:4059-65. 2014
132. Risk Stratification in Hormone-sensitive Metastatic Prostate Cancer: More Questions than Answers..  European urology.  68:205-6. 2014
133. Reply to Aaron M. Potretzke, Jeffrey A. Larson and Sam B. Bhayani's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9..  European urology.  67:e21-2. 2014
134. Reply to Homayoun Zargar, Rafael F. Coelho and Jihad H. Kaouk's Letter to the Editor re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9..  European urology.  67:e24-5. 2014
135. Reply to sarcopenia is more than simply documenting low skeletal muscle mass..  Cancer.  121:159-60. 2014
136. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy..  Prostate cancer and prostatic diseases.  17:332-7. 2014
137. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma..  Urologic oncology.  33:67.e15-23. 2014
138. Re: Sarcopenia as a predictor of complications and survival following radical cystectomy: A. B. Smith, A. M. Deal, H. Yu, B. Boyd, J. Matthews, E. M. Wallen, R. S. Pruthi, M. E. Woods, H. Muss and M. E. Nielsen. J Urol 2014; 191: 1714-1720..  The Journal of urology.  192:1582-3; discussion 1583. 2014
139. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses..  European urology.  67:252-9. 2014
140. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma..  The Journal of urology.  192:1620-7. 2014
141. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality..  Cancer.  120:2910-8. 2014
142. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy..  World journal of urology.  33:373-9. 2014
143. Psychosocial aspects of active surveillance..  Current opinion in urology.  23:273-7. 2013
144. Midterm oncological outcomes of laparoscopic vs open radical prostatectomy (RP)..  BJU international.  112:190-7. 2013
145. Uncertainty and perception of danger among patients undergoing treatment for prostate cancer..  BJU international.  111:E84-91. 2012
146. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma..  European urology.  63:486-92. 2012
147. Bladder diverticula in children..  Journal of pediatric urology.  9:129-38. 2012
148. Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension..  Urology.  78:121-5. 2011
149. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice..  The Journal of clinical investigation.  118:2592-9. 2008
150. Sampling frequencies and measurement error for linear and temporal gait parameters in primate locomotion..  Journal of human evolution.  49:665-79. 2005